We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Don’t invest in Neil Woodford’s Equity Income Fund until you’ve read this

Is Neil Woodford’s Equity Income fund really what it says it is?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Fund manager Neil Woodford has an excellent reputation, and a phenomenal track record of generating wealth for his investors. Indeed, if you had invested £10,000 with Woodford when he started out in 1989, your portfolio would now be worth over £300,000, twice the amount had the capital been invested in the FTSE All-Share index. So it’s no surprise that Woodford’s Equity Income fund consistently ranks among the most popular investment funds in the UK.

However if you’ve been thinking about investing hard-earned capital in Woodford’s fund, there’s a few things you should understand first.

XXX

Equity income

Equity income funds can provide an excellent foundation to many investment portfolios, as they aim to generate a rising income along with some capital growth over the long term. The fund manager will generally look to invest in mature, well-established businesses that pay regular dividends to shareholders. While the investment universe is diverse, it’s common to see blue-chip companies in the financials, healthcare, oil & gas, and consumer goods sectors making up a significant proportion of fund holdings.

A glance across the equity income fund sector reveals that many funds look quite similar, sharing key holdings. That’s why I was surprised recently when I examined Neil Woodford’s portfolio holdings. It’s fair to say that Woodford’s Equity Income fund isn’t your average equity income fund.

Actively managed

The first thing investors should understand about Woodford’s fund is that it’s very much ‘actively managed’. This means the fund manager isn’t simply aiming to replicate the returns of the market, but instead add value by picking his own stocks. Woodford isn’t afraid to make bold investment decisions, and as a result, the fund may not behave like the market at times. 

Under the bonnet

The next thing to be aware of is the composition of the portfolio. Woodford is transparent about his portfolio holdings and the full list of holdings as of 31 December 2016 can be found here. I’d recommend taking a look, because when I peered under the bonnet recently, I was quite surprised by some of the holdings. 

As can be seen below, the top 10 holdings are fairly standard for an equity income fund with a focus on FTSE 100 dividend champions, although there are a few unorthodox names in Prothena, Allied Minds, and Theravance Biopharma 

Woodford Holdings 1-10

1

AstraZeneca

8.12%

2

GlaxoSmithKline

7.81%

3

Imperial Brands

7.33%

4

British American Tobacco

6.24%

5

Legal & General

5.48%

6

Provident Financial

5.08%

7

AbbVie

3.31%

8

Prothena

2.86%

9

Allied Minds

2.27%

10

Theravance Biopharma

2.25%

Source: Woodfordfunds.com

However, looking beyond the top 10 holdings, Woodford really starts to shake things up, with less focus on well-known mainstream companies. 

Woodford Holdings 11-20

11

Benevolent AI (unquoted)

2.21%

12

Capita

2.20%

13

Babcock International

1.98%

14

NewRiver REIT

1.69%

15

Lancashire

1.66%

16

Alkermes

1.59%

17

BCA Marketplace

1.36%

18

Burford Capital

1.36%

19

G4S

1.36%

20

Next

1.32%

Source: Woodfordfunds.com

And by the time we get to the bottom of the portfolio, many of the companies he has invested in are unheard of and in fact, unquoted. 

Woodford Holdings 110-119

110

e-Therapeutics

0.03%

111

Genomics (unquoted)

0.03%

112

Halosource Reg S

0.03%

113

Synairgen

0.03%

114

Viamet (unquoted)

0.03%

115

Emba (unquoted)

0.02%

116

Evofem (unquoted)

0.02%

117

Emba – Series 2 (unquoted)

0.01%

118

Evofem C (unquoted)

0.01%

119

Sphere Medical

0.01%

Source: Woodfordfunds.com 

Healthcare bias

It’s also worth noting the strong bias towards the healthcare sector and Woodford has made it clear that he’s bullish on the long-term prospects of this sector. However, while he’s got large positions in the big boys of the pharma world, I’m quite surprised by just how many smaller, unproven healthcare holdings are in the portfolio, many of which aren’t even listed.

So what does this all mean? Has Woodford lost his focus? Do his poor performance figures over the last 12 months mean it’s time to ditch the fund manager? In my opinion, the answer to these questions is no, given his long-term track record. Having said that, I believe it’s important that investors understand exactly what they’re investing in before they invest in Woodford’s Equity Income fund.

Edward Sheldon has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »